Talaris Therapeutics to Participate at Two Upcoming Virtual Investor Conferences

Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases, and certain severe non-malignant blood, immune and metabolic disorders, today announced that members of its senior management team will participate at the following investor conferences:

Morgan Stanley Virtual 19th Annual Global Healthcare ConferenceFireside Chat Date: Monday, September 13, 2021Time: 5:00 PM ET

SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases & Genetic Medicines 1x1 EventDate: September 22-23, 2021

A live webcast of the fireside chat at the Morgan Stanley Virtual 19th Annual Global Healthcare Conference will be available on the investors section of the Talaris website at www.talaristx.com. After the live webcast, the event will remain archived on the Talaris website for 90 days.

About Talaris TherapeuticsTalaris Therapeutics, Inc. is a late-clinical stage biopharmaceutical company developing investigational, one-time, allogeneic cell therapies with the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases, and certain severe non-malignant blood, immune and metabolic disorders. Talaris maintains corporate offices in Boston, MA, and its cell processing facility in Louisville, KY. For additional information, visit talaristx.com, and follow us on Twitter, LinkedIn and Facebook.

Media ContactLisa RaffenspergerTen Bridge [e-mail][phone]

Investor ContactChris BrinzeyWestwicke, an ICR [e-mail] [phone]